Vanda Pharmaceuticals Inc. filed a Form 8-K on November 20, 2026, disclosing that it entered into a Confidential Settlement and License Agreement with MSN Pharmaceuticals Inc. and MSN Laboratories Private Limited on November 16, 2026, resolving patent infringement litigation over a generic version of HETLIOZ LQ (tasimelteon suspension, 4 mg/ml).
Key Highlights
- Settlement reached: Vanda and MSN resolved patent infringement litigation pending in the U.S. District Court for the District of Delaware, according to the filing.
- Non-exclusive, royalty-free license: Vanda granted MSN a non-exclusive, royalty-free license to manufacture, import, and market its generic tasimelteon oral suspension in the U.S.
- License Effective Date: The agreement sets the License Effective Date in the first quarter of 2040, with provisions for earlier market entry under specified circumstances.
- Pre-launch rights: MSN received limited pre-launch manufacturing and import rights beginning 180 days before the License Effective Date, and may begin customer discussions 30 days before, and pricing and contracting discussions 14 days before that date.
- Patent acknowledgment: MSN acknowledged that the patents asserted in the litigation are valid and enforceable with respect to its ANDA product, and agreed not to challenge them, subject to certain exceptions.
- Regulatory review required: The filing states that Vanda and MSN are required by law to submit the Settlement Agreement to the U.S. Federal Trade Commission and the U.S. Department of Justice for review.
- Most-favored terms clause: Vanda agreed that if it later grants any other party more favorable terms regarding market-entry timing or pre-launch rights, MSN will receive the benefit of those terms.
Vanda and MSN Resolve HETLIOZ LQ Generic Patent Dispute
According to the filing, Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) entered the Settlement Agreement on November 16, 2026, to resolve litigation captioned Vanda Pharmaceuticals Inc. v. MSN Pharmaceuticals Inc. and MSN Laboratories Private Limited. In that case, Vanda alleged that MSN's Abbreviated New Drug Application infringed certain U.S. patents owned by Vanda covering HETLIOZ LQ (tasimelteon suspension, 4 mg/ml). MSN's ANDA sought approval to market a generic version of that product in the U.S.
The filing describes several circumstances under which MSN could enter the market before the first quarter of 2040 License Effective Date. These include expiration of the licensed patents, a final court decision holding the licensed patents invalid, unenforceable, or not infringed, and the launch of an authorized generic or a licensed generic version of HETLIOZ LQ. Early entry could also occur if certain unlicensed third-party generic launches proceed without Vanda enjoining or stopping them within a specified period. Additionally, the filing states, MSN may supply its product before the License Effective Date if the FDA declares a drug shortage after Vanda voluntarily withdraws HETLIOZ LQ for reasons other than safety or efficacy.
The filing states that the parties will submit a stipulated order to the Court dismissing all claims in the litigation and will also submit a consent judgment and permanent injunction for the Court's approval. That injunction would bar MSN from making, using, importing, offering for sale, or selling its generic tasimelteon oral suspension except under a license from Vanda. The complete text of the Settlement Agreement is to be filed as an exhibit to Vanda's Annual Report on Form 10-K for the fiscal year ending December 31, 2026, according to the disclosure.
What Was Disclosed
Vanda Pharmaceuticals disclosed a Confidential Settlement and License Agreement with MSN settling HETLIOZ LQ patent litigation, granting MSN a non-exclusive, royalty-free license effective in the first quarter of 2040, subject to specified early-entry provisions and regulatory review requirements.




Please wait processing your request...